VNOV on OTC
VitaNova Life Sciences Corp
VitaNova Life Sciences Corp is an American wholesale-apparel company based in New York, listed on OTC (VNOV).1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Global Fashion Group, Stark Focus Group, Inc. or Weyco Group, or pick any stock.
- TickerVNOV on OTC1
- IndustryWholesale-Apparel, Piece Goods & Notions1
- HeadquartersNew York, New York1
- Incorporated inNV3
- Business address39 E. Broadway, Ste 603, New York, Ny 100023
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
Company provides consulting services to its clients with regards to funding and other financial matters.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Dietary Supplement Products brought in 64% of the revenue VitaNova Life Sciences Corp broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Dietary Supplement Products | $2.7M | $1.9M |
| Sale Of Food Products | $1.1M | |
| Consulting Service Income | $10.8K | $15.0K |
Business segments
Dietary Supplement brought in 64% of the revenue VitaNova Life Sciences Corp broke down this way in fiscal 2026.
Business segments by year
| Business segments | 2025 | 2026 |
|---|---|---|
| Dietary Supplement | $2.7M | $1.9M |
| Food Products | $1.1M | |
| Other | $15.0K |
Regions
Unites States Of America brought in 89% of the revenue VitaNova Life Sciences Corp broke down this way in fiscal 2026.
Regions by year
| Regions | 2025 | 2026 |
|---|---|---|
| Unites States Of America | $1.2M | $2.7M |
| Hong Kong | $1.1M | $345.6K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue70¢$2.1M
- Other costs29¢$866.7K
- Income tax1¢$43.9K
Out of $3.0M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2026
- Kept or used elsewhere100¢$814.4K
Out of $814.4K of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Revenue, net | $3.0M | $2.7M |
| Cost of revenue | -$2.1M | -$1.1M |
| Gross profit | $910.6K | $1.6M |
| Sales and distribution expenses | -$2.9K | -$7.7K |
| Personnel and benefit costs | -$170.3K | -$201.6K |
| General and administrative expenses | -$733.8K | -$158.1K |
| Total operating expenses | -$907.0K | -$367.4K |
| Income from operations | $3.6K | $1.2M |
| Interest expense | $0 | -$4.5K |
| Sundry income | $3.0K | $496 |
| Total other income (expenses), net | $3.0K | -$4.0K |
| Income before income tax | $6.6K | $1.2M |
| Income tax expense | -$43.9K | -$353.6K |
| Net income (loss) | -$37.3K | $850.7K |
| Net income (loss) per share, basic | -$0.00 | $0.10 |
| Weighted average number of shares outstanding - basic | 8.3M shares | 8.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-04-30 | 2025-04-30 | 2024-04-30 |
|---|---|---|---|
| Cash | $1.6M | $782.8K | |
| Accounts receivable, net | $726.7K | $1.3M | |
| Advance to vendors | $0 | $158.8K | |
| Inventories | $105.6K | $44.2K | |
| Other current assets | $950 | $3.4K | |
| Total current assets | $2.4M | $2.3M | |
| Deferred tax assets | $16.0K | $0 | |
| Total noncurrent assets | $16.0K | $0 | |
| TOTAL ASSETS | $2.4M | $2.3M | |
| Accounts payable | $208.8K | $0 | |
| Accrued expenses and other current liabilities | $79.0K | $60.9K | |
| Income tax payable | $108.0K | $286.7K | |
| Total current liabilities | $395.8K | $347.6K | |
| TOTAL LIABILITIES | $395.8K | $347.6K | |
| Preferred Stock, $0.001 par value; 10,000,000 shares authorized including 3,000,000 shares Series A Preferred Stock designated; nil shares issued and outstanding | $0 | $0 | |
| Common Stock, $0.001 par value; 200,000,000 shares authorized; 8,337,454 shares issued and outstanding | $8.3K | $8.3K | |
| Additional paid-in capital | $1.0M | $1.0M | |
| Shares to be issued | $182.4K | $3.0K | |
| Retained earnings | $830.4K | $867.7K | |
| Total Shareholders' Equity | $2.1M | $1.9M | $1.1M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $2.4M | $2.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 8.3M shares | 8.3M shares | |
| Common stock, shares outstanding | 8.3M shares | 8.3M shares |
| Period ending | 2026-04-30 | 2025-04-30 | 2024-04-30 |
|---|---|---|---|
| Cash | $1.6M | $782.8K | |
| Accounts receivable, net | $726.7K | $1.3M | |
| Advance to vendors | $0 | $158.8K | |
| Inventories | $105.6K | $44.2K | |
| Other current assets | $950 | $3.4K | |
| Total current assets | $2.4M | $2.3M | |
| Deferred tax assets | $16.0K | $0 | |
| Total noncurrent assets | $16.0K | $0 | |
| TOTAL ASSETS | $2.4M | $2.3M | |
| Accounts payable | $208.8K | $0 | |
| Accrued expenses and other current liabilities | $79.0K | $60.9K | |
| Income tax payable | $108.0K | $286.7K | |
| Total current liabilities | $395.8K | $347.6K | |
| TOTAL LIABILITIES | $395.8K | $347.6K | |
| Preferred Stock, $0.001 par value; 10,000,000 shares authorized including 3,000,000 shares Series A Preferred Stock designated; nil shares issued and outstanding | $0 | $0 | |
| Common Stock, $0.001 par value; 200,000,000 shares authorized; 8,337,454 shares issued and outstanding | $8.3K | $8.3K | |
| Additional paid-in capital | $1.0M | $1.0M | |
| Shares to be issued | $182.4K | $3.0K | |
| Retained earnings | $830.4K | $867.7K | |
| Total Shareholders' Equity | $2.1M | $1.9M | $1.1M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $2.4M | $2.3M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 8.3M shares | 8.3M shares | |
| Common stock, shares outstanding | 8.3M shares | 8.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Net income (loss) | -$37.3K | $850.7K |
| Interest expenses | $0 | $4.5K |
| Share-based compensation | $179.4K | $2.0K |
| Deferred tax assets | -$16.0K | $0 |
| Bad debt expense | $61.4K | $0 |
| Inventories | -$61.4K | $88.6K |
| Accounts receivable | $478.8K | -$1.3M |
| Advance to vendor | $158.8K | $302.1K |
| Other current assets | $2.5K | $2.6K |
| Accounts payable | $208.8K | -$5.2K |
| Accrued expenses and other current liabilities | $18.1K | -$7.5K |
| Income tax payable | -$178.7K | $221.8K |
| Net cash provided by operating activities | $814.4K | $192.8K |
| Repayment to related parties | $0 | -$3.0K |
| Net cash used in financing activities | $0 | -$3.0K |
| Net change in cash | $814.4K | $189.8K |
| Interest paid | $0 | $0 |
| Income taxes paid | $238.6K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
VitaNova Life Sciences Corp sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
- VitaNova Life Sciences Corp New York, New York
- Nutripeak Trading Corporation Subsidiary · Nevada, United States
- VitaNova Global Foods Corporation Subsidiary · Nevada, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What VitaNova Life Sciences Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $105.6K2 Apr 30, 2026 | $44.2K2 Apr 30, 2025 | +138.7% |
| Finished goods | $105.6K2 Apr 30, 2026 | $44.2K2 Apr 30, 2025 | +138.7% |
Properties, in its own words
Our property is located at 31 Lakeland Ave, Babylon, New York 11702, where we lease about 700 square feet of storage space. The lease for this storage is on a month-to-month basis. We consider our storage space to be adequate for our current needs. We believe that other suitable storage space would be available if we move to a different location upon the expiration of our current lease.
Our principal executive offices are located at 39 E Broadway, Suite 603, New York, NY 10002. Our telephone number is +1 (516) 886-8888.
Item 2 of the 10-K filed Jul 29, 2026.5
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Mar 18, 20268-K Executive or director change16
- Feb 25, 20268-K Executive or director change17
- Jan 27, 20268-K Other events18
- Jan 13, 20268-K Bylaws or fiscal year changed; Other events19
- Oct 7, 20258-K Other events20
- Jun 10, 20248-K Change of auditor21
- Feb 5, 20248-K Entered a material agreement; Unregistered sale of shares22
- Jan 12, 20248-K Executive or director change; Other events23
- Sep 14, 20238-K Change in control; Executive or director change24
- Jun 15, 20238-K Change in control; Executive or director change25
- Feb 16, 20228-K Entered a material agreement26
- Dec 2, 20218-K Change of auditor27
Filings
47 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 12 major events, 15 other. The latest 20:
- Sep 14, 202610-Q FORM 10-Q FOR JUL 2026 EDGAR
- Jul 29, 202610-K FORM 10-K FOR APR 2026 EDGAR
- Mar 18, 20268-K CURRENT REPORT EDGAR
- Mar 16, 202610-Q FORM 10-Q FOR JAN 2026 EDGAR
- Feb 25, 20268-K CURRENT REPORT EDGAR
- Jan 27, 20268-K CURRENT REPORT EDGAR
- Jan 13, 20268-K EDGAR
- Dec 15, 202510-Q FORM 10-Q FOR OCT 2025 EDGAR
- Oct 7, 20258-K EDGAR
- Sep 12, 202510-Q FORM 10-Q FOR JULY 2025 EDGAR
- Jul 24, 202510-K FORM 10-K FOR APRIL 2025 EDGAR
- Mar 17, 202510-Q FORM 10-Q FOR JAN 2025 EDGAR
- Dec 13, 202410-Q FORM 10-Q FOR OCT 2024 EDGAR
- Sep 10, 202410-Q FORM 10-Q FOR JULY 2024 EDGAR
- Jul 29, 202410-K FORM 10-K FOR APRIL 2024 EDGAR
- Jun 10, 20248-K CURRENT REPORT EDGAR
- Mar 11, 202410-Q FORM10-Q FOR JANUARY 2024 EDGAR
- Feb 5, 20248-K CURRENT REPORT EDGAR
- Jan 12, 20248-K EDGAR
- Dec 15, 202310-Q EDGAR
The 47 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How VitaNova Life Sciences Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARVitaNova Life Sciences Corp1
- CIK0001699709
- Employer ID (EIN)35-25837625
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company5
- Incorporated inNevada5
- Fiscal year endsApril 301
- Industry code (SIC)5130 Wholesale-Apparel, Piece Goods & Notions1
- SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
- Business address39 E. Broadway, Ste 603, New York, NY 100021
- Phone516-886-88881
- Shares outstanding8,337,454 as of Sep 14, 202615
- Public float$24.1M as of Oct 31, 20255
- AuditorSimon & Edward, LLP, Los Angeles County, California PCAOB ID 2485; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceJun 14, 20171
- Filings97 in all: 10-Q (27), 8-K (23), 10-K (9), UPLOAD (8), S-1/A (7), POS AM (5), EFFECT (4), CORRESP (3)1
All 14 form types
NT 10-Q (3), 10-Q/A (2), NT 10-K (2), S-1 (2), AW (1), SC 14F1 (1)
- Latest filingsAnnual report (10-K) Jul 29, 2026
Quarterly report (10-Q) Sep 14, 2026
Latest 8-K (8-K) Mar 18, 2026
Risk factors and legal proceedings
Legal proceedings
We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation, and there are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our Company.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARExecutive or director change
- 17SEC EDGARExecutive or director change
- 18SEC EDGAROther events
- 19
- 20SEC EDGAROther events
- 21SEC EDGARChange of auditor
- 22
- 23
- 24
- 25
- 26SEC EDGAREntered a material agreement
- 27SEC EDGARChange of auditor